This systematic review traced the historical efforts to rename polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS), screening 30 eligible papers (1995–2026) via PRISMA 2020 methodology across Medline and Embase.
A 2026 global, patient-co-led renaming process involving 56 organisations and 22,000+ survey respondents achieved 97% consensus on the new name PMOS, with early adoption seen across coding systems, clinical guidelines, professional societies, and media.
The review relies on published literature only (30 papers), which may underrepresent grey literature or unpublished stakeholder efforts; the long-term impact of the rename on clinical outcomes and diagnostic rates has not yet been evaluated.
Clinicians should begin adopting the term PMOS in practice, documentation, and patient communication, as the rename reflects the broader endocrine-metabolic nature of the condition and has achieved near-universal consensus. Awareness of the updated terminology will be important for coding, referrals, and patient education.
